D. Weber

发表

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.

F. Saad, S. Hotte, S. Sridhar, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral Trofosfamide in Elderly and/or Heavily Pretreated Patients with Metastatic Lung Cancer

P. Reichardt, S. Hegewisch‐Becker, T. Wagner, 2000, Oncology Research and Treatment.

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).

C. Bokemeyer, L. Kanz, M. Schittenhelm, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

N. Saijo, F. Rojo, A. Ohtsu, 2005 .

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

F. Rojo, W. Schmiegel, T. Südhoff, 2006, British Journal of Cancer.

Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST).

F. Ciardiello, Y. Humblet, M. Peeters, 2007 .

Preventing patupilone-induced diarrhea with high-dose corticosteroids.

S. Hotte, C. Kollmannsberger, S. Sridhar, 2010 .

Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

B. Mellado, E. Tan, D. Castellano, 2010 .

Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma

Gina Brown, A. Wotherspoon, D. Cunningham, 2005 .

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

M. Dimopoulos, D. Bae, P. Schwartz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial

Y. Yonekawa, K. Frei, S. Hofer, 2012, Oncology.

A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

W. M. Smit, A. Oza, H. Hirte, 2012 .

Pharmacological Activity Of Cb-103-An Oral Pan-Notch Inhibitor With A Novel Mode Of Action

J. Bourquin, M. Murone, F. Radtke, 2017 .

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.

P. Nuciforo, D. Rossi, A. Stathis, 2018 .

Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma

U. Vanhoefer, T. Trarbach, S. Seeber, 2005 .

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

W. Schmiegel, T. Südhoff, U. Graeven, 2006, British Journal of Cancer.